The JAK2 46/1 haplotype: A marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?

Haematologica

Volumn 96, Issue 11, 2011, Pages 1575-1579

  Hermouet, Sylvie ^a,b   Vilaine, Mathias ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME 9P; CHRONIC MYELOID LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; CROHN DISEASE; DNA REPLICATION; EDITORIAL; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC PREDISPOSITION; HAPLOTYPE; HUMAN; INFECTION; INFLAMMATION; INTRON; JAK2 GENE; MYELOID METAPLASIA; POLYCYTHEMIA VERA; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTHEMIA; VEIN THROMBOSIS;

FEMALE; GERM-LINE MUTATION; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, ACUTE; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 80355126571     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.055392     Document Type: Editorial

References (21)

1. Pardanani A, Fridley BL, Lasho TL, Gilliland DG, Tefferi A. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood. 2008;111(5):2785-2789.
2. Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009;41(4):455-459.
3. Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, et al. JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nat Genet. 2009;41(4):446-449.
4. Olcaydu D, Harutyunyan A, Jäger R, Berg T, Gisslinger B, Pabinger I, et al. A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms. Nat Genet. 2009;41(4):450-454.
5. Tefferi A, Lasho TL, Patnaik MM, Finke CM, Hussein K, Hogan WJ, et al. JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. Leukemia. 2010;24(1):105-109.
6. Jones AV, Campbell PJ, Beer PA, Schnittger S, Vannucchi AM, Zoi K, et al. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood. 2010;115(22):4517-4523.
7. Smalberg JH, Koehler E, Darwish Murad S, Plessier A, Seijo S, Trebicka J, et al; European Network for Vascular Disorders of the Liver (EN-Vie). The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood. 2011;117(15):3968-3973.
8. Kouroupi E, Kiladjian JJ, Chomienne C, Dosquet C, Bellucci S, Valla D, et al. The JAK2 46/1 haplotype in splanchnic vein thrombosis. Blood. 2011;117(21):5777-5778
9. Andrikovics H, Nahajevszky S, Koszarska M, Meggyesi N, Bors A, Halm G, et al. JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia. Leukemia. 2010;24(10):1809-1813.
10. Nahajevszky S, Andrikovics H, Batai A, Adam E, Bors A, Csomor J, et al. The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia. Haematologica. 2011;96(11):1613-1618.
11. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008;40(8):955-962.
12. Ferguson LR, Han DY, Fraser AG, Huebner C, Lam WJ, Morgan AR, et al. Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population. Mutat Res. 2010;690(1-2):108-115.
13. Cleyrat C, Jelinek J, Girodon F, Boissinot M, Ponge T, Harousseau J-L, et al. JAK2 mutation and disease phenotype: A double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5. Leukemia. 2010;24(5):1069-1073.
14. Vilaine M, Olcaydu D, Harutyunyan A, Bergeman J, Mourad T, Ramée J-F, et al. Homologous recombination of wild-type JAK2, a novel early step in he development of myeloproliferative neoplasm. Blood. in press.
15. Lippert E, Boissinot M, Kralovics R, Girodon F, Dobo I, Praloran V, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006;108(6):1865-1867.
16. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, Skoda RC. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931-3940.
17. Qi X, Shao M, Peng H, Bi Z, Su Z, Li H. In vitro differentiation of bone marrow stromal cells into neurons and glial cells and differential protein expression in a two-compartment bone marrow stromal cell/neuron coculture system. J Clin Neurosci. 2010;17(7):908-913.
18. Brandt B, Kemming D, Packeisen J, Simon R, Helms M, Feldmann U, et al. Expression of early placenta insulin-like growth factor in breast cancer cells provides an autocrine loop that predominantly enhances invasiveness and motility. Endocr Relat Cancer. 2005;12(4):823-837.
19. Corre-Buscail I, Pineau D, Boissinot M, Hermouet S. Erythropoietinindependent erythroid colony formation by bone marrow progenitors exposed to interleukins 11 and 8. Exp Hematol. 2005;33(11):1299-1308.
20. Boissinot M, Cleyrat C, Vilaine M, Jacques Y, Corre I, Hermouet S. Antiinflammatory hepatocyte growth factor and interleukin-11 are overexpressed in polycythemia vera and contribute to the growth of mutated erythroblasts independently of JAK2V617F. Oncogene. 2011;30(8):990-1001.
21. Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica. 2011;96(2):315-318.